Aurisco(SH:605116) Shang Hai Zheng Quan Bao·2026-01-12 18:13Core Viewpoint - The company, Aorite Pharmaceutical Co., Ltd., has announced an adjustment to the maximum repurchase price of its shares from RMB 24.71 per share to RMB 35.00 per share, while keeping other aspects of the repurchase plan unchanged [2][9]. Group 1: Repurchase Plan Overview - The company approved a share repurchase plan on January 21, 2025, with a total fund amount between RMB 60 million and RMB 120 million, and an initial maximum repurchase price of RMB 25.00 per share [4]. - The maximum repurchase price was adjusted to RMB 24.71 per share due to the company's 2024 annual equity distribution, effective from June 20, 2025 [4]. Group 2: Progress of Share Repurchase - As of the announcement date, the company has repurchased a total of 2,627,238 shares, representing 0.65% of the total share capital, with a total expenditure of RMB 55,124,396.68 [5]. Group 3: Adjustment Details - The adjustment of the repurchase price limit is based on the recent stock price performance, which has consistently exceeded the previous limit, reflecting the company's confidence in its future development [6]. - The new maximum repurchase price is below 150% of the average stock price over the last 30 trading days prior to the adjustment [6]. Group 4: Impact of the Adjustment - The adjustment complies with relevant regulations and is expected to facilitate the smooth implementation of the repurchase plan without adversely affecting the company's operations, financial status, or future development [7]. - The adjustment will not change the company's control or its listing status, ensuring that the share distribution remains compliant with listing requirements [7].